OMA Guidelines Bundle

Obesity Pharmacotherapy Supplements 2026

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1544296

Contents of this Issue

Navigation

Page 5 of 19

6 Medication and Supplement History (cont'd) Medications Associated With Weight Changes Medication Class Weight Gain Antidepressants • Citalopram • Escitalopram • Fluvoxamine • Paroxetine • Lithium • MAOI • TCAs • Miratazapine • Doxepin Antipsychotics • Clozapine • Risperidone • Olanzapine • Quetapine • Aripiprazole Anticonvulsants • Carbamazepine • Gapabentin • Valproic acid • Pregablin Mood stabilizers • Lithium Antidiabetic agents • Insulin • Sulfonylureas • Thiazolindinediones Antihypertensives • Prazosin • Doxazosin • Terazosin • Metoprolol tartrate • Propranolol • Atenolol Contraceptives and hormones • Depo-medroxyprogesterone acetate • Megestrol acetate Antiretrovirals • Protease inhibitors • Integrase inhibitors Steroids • Corticosteroids • Progestins • Glucocorticoids Antihistamines and anticholinergics • Diphenhydramine • Cetirizine • Hydroxyzine • Meclizine • Cyproheptadine

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity Pharmacotherapy Supplements 2026